Aptinyx to be Added to Russell 2000® Index
June 26 2020 - 8:37AM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, will be added as a member of
the US small-cap Russell 2000® Index. The addition will be
effective after the US market opens on June 29, 2020 as part of the
2020 Russell US Indexes annual reconstitution.
Inclusion in the Russell 2000® Index, which remains in place for
one year, is based on membership in the broad-market Russell 3000®
Index. Russell US Indexes are widely used by investment managers
and institutional investors as the basis for index funds and as
benchmarks for active investment strategies. Approximately $9
trillion in assets are benchmarked against Russell US Indexes.
Russell US Indexes are part of FTSE Russell’s suite of index
offerings.
“We are pleased with the inclusion of Aptinyx in the Russell
2000® Index,” said Ashish Khanna, CFO and chief business officer of
Aptinyx. “This will enhance the visibility of our company among the
investment community and highlight our important efforts to advance
the development of our pipeline of novel NMDA receptor modulators
for patients suffering from challenging CNS disorders.”
For more information on the Russell 2000® Index and the Russell
US Indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
www.aptinyx.com.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
For more information, visit www.ftserussell.com
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, including therapeutic
effects of the company’s product candidates and discovery platform.
Risks that contribute to the uncertain nature of the
forward-looking statements include: the effect of COVID-19 on our
business and financial results, including with respect to
disruptions to our clinical trials, business operations, and
ability to raise additional capital; the success, cost, and timing
of the company’s product candidate development activities and
planned clinical studies; the company’s ability to execute on its
strategy; the company’s estimates regarding expenses, future
revenue, and capital requirements; as well as those risks and
uncertainties set forth in the company’s most recent annual report
on Form 10-k and subsequent filings with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Aptinyx undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200626005041/en/
Investor & Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Sep 2023 to Sep 2024